{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzllp1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzllp1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/48\\\/6\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/48\\\/6\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/48\\\/6\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/48\\\/6\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\u003Cp id=\u0022p-1\u0022\u003EThe antibacterial agent tedizolid is effective against Gram-positive pathogens, including resistant strains of methicillin-resistant \u003Cem\u003EStaphylococcus aureus\u003C\/em\u003E. In the ESTABLISH-1 and -2 trials, it was noninferior to linezolid for treating acute bacterial skin and skin structure infections; this remained true in 3 pooled analyses of these studies, regardless of route of administration, infection type, or whether a causative pathogen was identified at baseline.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Eacute bacterial skin and skin structure infections\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EABSSSI\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Etedizolid\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Elinezolid\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EESTABLISH-1\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EESTABLISH-2\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eefficacy\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Esafety\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Elower extremity\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eroute of administration\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ebaseline pathogens\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eantibacterial\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ebacterial infections\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Einfectious diseases clinical trials\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003EThree presentations reported similar efficacy and safety for tedizolid vs linezolid in patients with acute bacterial skin and skin structure infections (ABSSSIs) regardless of route of administration, type of infection, or whether a causative pathogen was identified at baseline. The reports were based on pooled data from 2 phase 3 clinical trials, ESTABLISH-1 and ESTABLISH-2 [Shorr AF et al. \u003Cem\u003EAntimicrob Agents Chemother\u003C\/em\u003E. 2015]. Both trials were randomized, double-blind, multicenter trials that demonstrated the noninferiority of tedizolid (200 mg once daily for 6 days) to linezolid (600 mg twice daily for 10 days) in patients with ABSSSIs. Patients in ESTABLISH-1 [Prokocimer P et al. \u003Cem\u003EJAMA\u003C\/em\u003E. 2013] received only oral drug, while ESTABLISH-2 [Moran GJ et al. \u003Cem\u003ELancet Infect Dis\u003C\/em\u003E. 2014] patients received 2 or more intravenous doses, after which they could be switched to oral doses.\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EFor the pooled analysis, the primary study end point established by the FDA was early clinical response (\u2265\u200520% reduction in lesion area at 48 to 72 hours compared with baseline). The primary end point required by the European Medicines Agency was the investigator\u2019s assessment of clinical response at post-therapy evaluation (PTE). Secondary end points included clinical response at end-of-therapy (EOT) and results of microbiological efficacy analyses obtained from the primary ABSSSI site at baseline. Safety evaluations included an assessment of treatment-emergent adverse events (TEAEs). Early assessment occurred 48 to 72 hours post treatment, EOT assessment at days 11 to 13, and PTE at days 18 to 25.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EPatients (aged \u2265\u200518 years in ESTABLISH-1 and \u2265\u200512 years in ESTABLISH-2) with an ABSSSI (cellulitis or erysipelas, major cutaneous abscess, or wound infection) that had a lesion area of \u2265\u200575 cm\u003Csup\u003E2\u003C\/sup\u003E, and \u2265\u20051 regional or systemic sign of suspected infection documented to be associated with a gram-positive pathogen, were included in the studies. There were 664 patients in the tedizolid-treated group and 669 in the linezolid group.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EUsing the pooled data, Carisa De Anda, PharmD, Merck \u0026amp; Co, Inc, San Diego, California, USA, reported that there were no clinically meaningful differences in efficacy or adverse event (AE) rates between the intravenous-only, intravenous and oral, and oral-only groups following tedizolid or linezolid administration. Baseline demographics and clinical characteristics were similar between treatment groups. Lesion area was greater in the intravenous-only group but similar between drug treatment groups. More patients in the intravenous-only group had a lesion surface area \u0026gt;\u2005300 cm\u003Csup\u003E2\u003C\/sup\u003E. Methicillin-resistant \u003Cem\u003EStaphylococcus aureus\u003C\/em\u003E (MRSA) infection rates were higher in the oral-only group. Early clinical response rates were similar for the 3 routes of administration and drug treatments, and ranged from 85.4% to 76.1%; differences between treatment groups were small (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Early Clinical Response Rates by Route of AdministrationIV, intravenous.Reproduced with permission from C De Anda, PharmD.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-682159258\u0022 data-figure-caption=\u0022Early Clinical Response Rates by Route of AdministrationIV, intravenous.Reproduced with permission from C De Anda, PharmD.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16630\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cp id=\u0022p-6\u0022 class=\u0022first-child\u0022\u003EEarly Clinical Response Rates by Route of Administration\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003EIV, intravenous.\u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003EReproduced with permission from C De Anda, PharmD.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-9\u0022\u003ESimilar values were seen for clinical responses at PTE, but with an even smaller range (82.8% to 89.2%) and treatment differences (\u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Clinical Response Rates by Route of Administration at Post-therapy EvaluationIV, intravenous.Reproduced with permission from C De Anda, PharmD.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-682159258\u0022 data-figure-caption=\u0022Clinical Response Rates by Route of Administration at Post-therapy EvaluationIV, intravenous.Reproduced with permission from C De Anda, PharmD.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 2.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F2.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 2.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16631\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 2.\u003C\/span\u003E \u003Cp id=\u0022p-10\u0022 class=\u0022first-child\u0022\u003EClinical Response Rates by Route of Administration at Post-therapy Evaluation\u003C\/p\u003E\u003Cp id=\u0022p-11\u0022\u003EIV, intravenous.\u003C\/p\u003E\u003Cp id=\u0022p-12\u0022\u003EReproduced with permission from C De Anda, PharmD.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-13\u0022\u003EThere were no clinically meaningful differences in the rates of TEAEs or serious TEAEs based upon route of administration of tedizolid or linezolid. There were few drug-related TEAEs or TEAEs leading to discontinuation. Early and late clinical treatment response rates were high in ABSSSI patients, while the rates were similar regardless of route of administration or use of tedizolid vs linezolid.\u003C\/p\u003E\u003Cp id=\u0022p-14\u0022\u003EUsing the same pooled data, Warren Joseph, DPM, Roxborough Memorial Hospital, Philadelphia, Pennsylvania, USA, reported that once-daily (6 days) use of tedizolid had efficacy similar to 10 days of twice-daily linezolid for the treatment of lower-extremity ABSSSIs. Lower-extremity (mostly in the lower leg) ABSSSIs were seen in 270 patients in the tedizolid arm (270 of 664; 40.7%) and 282 patients in the linezolid arm (282 of 669; 42.2%). Baseline causative pathogens were isolated in 129 of 270 tedizolid and 145 of 282 linezolid patients; the majority were gram-positive aerobes (mainly \u003Cem\u003ES aureus\u003C\/em\u003E and \u003Cem\u003EStreptococcus pyogenes\u003C\/em\u003E). Cellulitis\/erysipelas, wound infections, and cutaneous abscess were documented in 58.0%, 25.9%, and 16.1%, respectively, of patients with lower-extremity ABSSSIs.\u003C\/p\u003E\u003Cp id=\u0022p-15\u0022\u003EEarly clinical responses were similar between treatment arms and across lower-extremity ABSSSI types (cellulitis\/erysipelas, wound infections, and major cutaneous abscess). However, in both treatment groups, response rates were lower for cellulitis compared with wound infection and major cutaneous abscess (\u003Ca id=\u0022xref-fig-3-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003EFigure 3\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F3\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F3.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Early Clinical Response by ABSSSI: Type of Infection in Lower ExtremityValues above brackets indicate treatment difference (95% CI).ABSSSI, acute bacterial skin and skin structure infection.Reproduced with permission from W Joseph, DPM.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-682159258\u0022 data-figure-caption=\u0022Early Clinical Response by ABSSSI: Type of Infection in Lower ExtremityValues above brackets indicate treatment difference (95% CI).ABSSSI, acute bacterial skin and skin structure infection.Reproduced with permission from W Joseph, DPM.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 3.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F3.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F3.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 3.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F3.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16632\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 3.\u003C\/span\u003E \u003Cp id=\u0022p-16\u0022 class=\u0022first-child\u0022\u003EEarly Clinical Response by ABSSSI: Type of Infection in Lower Extremity\u003C\/p\u003E\u003Cp id=\u0022p-17\u0022\u003EValues above brackets indicate treatment difference (95% CI).\u003C\/p\u003E\u003Cp id=\u0022p-18\u0022\u003EABSSSI, acute bacterial skin and skin structure infection.\u003C\/p\u003E\u003Cp id=\u0022p-19\u0022\u003EReproduced with permission from W Joseph, DPM.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-20\u0022\u003ESimilar findings were reported at PTE. No differences in rates of lower-extremity ABSSSI types were noted in postclinical responses between the tedizolid and linezolid treatment groups (\u003Ca id=\u0022xref-fig-4-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F4\u0022\u003EFigure 4\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F4\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F4.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Post-therapy Evaluations by ABSSSI: Type of Infection in Lower ExtremityValues above brackets indicate treatment difference (95% CI).ABSSSI, acute bacterial skin and skin structure infection.Reproduced with permission from W Joseph, DPM.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-682159258\u0022 data-figure-caption=\u0022Post-therapy Evaluations by ABSSSI: Type of Infection in Lower ExtremityValues above brackets indicate treatment difference (95% CI).ABSSSI, acute bacterial skin and skin structure infection.Reproduced with permission from W Joseph, DPM.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 4.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F4.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F4.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 4.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F4.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16633\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 4.\u003C\/span\u003E \u003Cp id=\u0022p-21\u0022 class=\u0022first-child\u0022\u003EPost-therapy Evaluations by ABSSSI: Type of Infection in Lower Extremity\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003EValues above brackets indicate treatment difference (95% CI).\u003C\/p\u003E\u003Cp id=\u0022p-23\u0022\u003EABSSSI, acute bacterial skin and skin structure infection.\u003C\/p\u003E\u003Cp id=\u0022p-24\u0022\u003EReproduced with permission from W Joseph, DPM.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-25\u0022\u003EResponse rate differences were noted between patients with lower-extremity ABSSSIs (5% to 8%) and those with ABSSSIs in non\u2013lower-extremity locations for early clinical responses but not for PTE responses (\u003Ca id=\u0022xref-fig-5-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F5\u0022\u003EFigure 5\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F5\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F5.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Early and Post-therapy Response Rates in Patients With Lower- and Non\u0026#x2013;Lower-Extremity LocationsValues above brackets indicate treatment difference (95% CI).LEI, lower-extremity infection.Reproduced with permission from W Joseph, DPM.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-682159258\u0022 data-figure-caption=\u0022Early and Post-therapy Response Rates in Patients With Lower- and Non\u0026#x2013;Lower-Extremity LocationsValues above brackets indicate treatment difference (95% CI).LEI, lower-extremity infection.Reproduced with permission from W Joseph, DPM.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 5.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F5.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F5.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 5.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/6\/F5.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16634\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 5.\u003C\/span\u003E \u003Cp id=\u0022p-26\u0022 class=\u0022first-child\u0022\u003EEarly and Post-therapy Response Rates in Patients With Lower- and Non\u2013Lower-Extremity Locations\u003C\/p\u003E\u003Cp id=\u0022p-27\u0022\u003EValues above brackets indicate treatment difference (95% CI).\u003C\/p\u003E\u003Cp id=\u0022p-28\u0022\u003ELEI, lower-extremity infection.\u003C\/p\u003E\u003Cp id=\u0022p-29\u0022\u003EReproduced with permission from W Joseph, DPM.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-30\u0022\u003ENo AE rate differences were noted between treatment groups (tedizolid, 36.8%; linezolid, 39.8%).\u003C\/p\u003E\u003Cp id=\u0022p-31\u0022\u003EThe purpose of the study conducted by Taylor Sandison, MD, Merck \u0026amp; Co, Inc, San Diego, California, USA, was to compare the efficacy of tedizolid in patients with ABSSSIs in whom no pathogen was isolated at baseline with that in patients who did have a confirmed pathogen. Using the same pooled data, tedizolid appeared to be an effective option for the treatment of ABSSSIs regardless of whether a causative pathogen was identified at baseline.\u003C\/p\u003E\u003Cp id=\u0022p-32\u0022\u003EOf the 664 patients randomized to tedizolid, 258 did not have a pathogen isolated at baseline. Microbiologic assessments were attempted in 207 patients with inconclusive results; in 51 patients, microbiologic assessments were not attempted. This latter group of patients had substantially larger lesion areas. Most infections were located in the lower extremities (54.7%) and diagnosed as cellulitis\/erysipelas (76%).\u003C\/p\u003E\u003Cp id=\u0022p-33\u0022\u003ETedizolid remains an effective treatment regardless of whether a pathogen had been isolated at baseline (\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/16635\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/16635\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16635\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \u003Cp id=\u0022p-34\u0022 class=\u0022first-child\u0022\u003EClinical Responses in Patients With and Without Baseline Pathogen Isolation Treated With Tedizolid\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-39\u0022\u003EThere were no differences in AEs, TEAEs, drug-related TEAEs, serious TEAEs, or TEAEs leading to discontinuation between tedizolid-treated patients regardless of the identification of a baseline pathogen. The most frequent TEAEs in patients with unknown pathogens were nausea (8.5%), headache (5.8%), and diarrhea (4.3%). Nausea (7.9%), abscess (7.7%), and headache (6.4%) were the most common TEAEs in patients with known baseline pathogens.\u003C\/p\u003E\u003Cp id=\u0022p-40\u0022\u003ETedizolid was generally well tolerated in patients with ABSSSIs regardless of whether a causative pathogen was identified, the route of administration, or the location of the infection. Only rarely was treatment discontinued due to AEs. Overall, the most common TEAEs were nausea, headache, diarrhea, vomiting, and abscess. Tedizolid has a high bioavailability and, with its route of administration variability, may allow for shorter hospitalizations, fewer hospitalization-related complications, and cost savings.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/48\/6.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzllp1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzllp1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nzllp1\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}